This preparation is suitable for patients who cannot swallow the solid oral form.
This preparation is used as an antiemetic.
Since there is currently a shortage, this product may be compounded to meet patients’ needs.
This drug is approved with restricted distribution for certain cases of erythema nodosum leprosum and multiple myeloma.
This delivery system utilizes a new dosage form.
This topical preparation may be used to treat Raynaud’s phenomenon and progressive diabetic foot ulcers.
This semisynthetic aminoglycoside antibiotic is presently in short supply.
Product shortages and lack of availability may render it necessary for the pharmacist to compound a suitable alternative.
This formulation can be compounded for use until the manufactured product—recently in short supply—is readily available.
A suitable biological safety cabinet should be employed, with excess
materials disposed of according to hazardous-drugs standard operating
procedures.
This compound contains six active ingredients with varying mechanisms of pain relief.
This preparation combines an emollient component, which is beneficial for cracked skin, with bacterial action.
Patients with orofacial neuropathic pain can benefit from this preparation.
This formulation should be prepared according to strict aseptic
technique by a pharmacist validated in aseptic compounding methods.
Tea tree oil, which is used to treat some skin disorders, has fungicidal and bactericidal properties.
Patients taking cholesterol-lowering drugs may use this preparation supplementally.
This form may be used by patients unable to take the oral solid form of this anticonvulsant.
This topical agent may be used for such infections as tinea pedis, tinea cruris, and tinea corporis.
This product warms up as it is smoothed into the skin, which may render it more viscous and rub-resistant.
This formulation is an alternative for patients who are unable to swallow the tablets.
For more articles, please check our archives.